Expert council resolution on the problem of diagnosis and treatment of resistant hypertension
A. O. Konradi,
E. I. Baranova,
A. S. Galyavich,
N. E. Zvartau,
N. A. Koziolova,
S. V. Nedogoda,
A. Yu. Falkovskaya,
A. I. Chesnikova https://doi.org/10.15829/1560-4071-2025-6543
EDN: JIQLMO
Abstract
On December 6, 2024, an Expert Council meeting was held in St. Petersburg on the problem of diagnosis and treatment of resistant hypertension (HTN). The importance of timely detection and treatment of patients with resistant hypertension is determined by a higher risk of myocardial infarction, stroke, heart failure and cardiovascular mortality compared to patients with uncontrolled HTN. The experts discussed the existing evidence base on a new class of aldosterone synthase inhibitors, in particular the baxdrostat.
About the Authors
A. O. Konradi
Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg
E. I. Baranova
Pavlov First Saint Petersburg State Medical University
St. Petersburg
A. S. Galyavich
Kazan State Medical University
Kazan
N. E. Zvartau
Almazov National Medical Research Center
St. Petersburg
N. A. Koziolova
Wagner Perm State Medical University
Perm
S. V. Nedogoda
Volgograd State Medical University
Volgograd
A. Yu. Falkovskaya
Cardiology Research Institute, Tomsk National Research Medical Center
Tomsk
A. I. Chesnikova
Rostov State Medical University
, Rostov-on-Don
References
1. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/1560-4071-2024-6117.
2. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.
3. Townsend RR. Pathogenesis of drug-resistant hypertension. Seminars in Nephrology, 2014;34(5):506-13. doi:10.1016/j.semnephrol.2014.08.004.
4. Buffolo F, Tetti M, Mulatero P, et al. Aldosterone as a Mediator of Cardiovascular Damage. Hypertension. 2022;79:1899-911. doi:10.1161/HYPERTENSIONAHA.122.17964.
5. Ebinger JE, Kauko A, Finn G, et al. Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry. European Journal of Preventive Cardiology. 2023;30:960-8. doi:10.1093/eurjpc/zwad066.
6. Cluett JL, William JH. Evaluation and Management of Resistant Hypertension: Core Curriculum 2024. Am J Kidney Dis. 2024;84(3):374-87. doi:10.1053/j.ajkd.2024.04.009.
7. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45:39124018. doi:10.1093/eurheartj/ehae178.
8. Primenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475-81. doi:10.1161/HYPERTENSIONAHA.109.131235.
9. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):205968. doi:10.1016/S0140-6736(15)00257-3.
10. Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474-82. doi:10.1093/eurheartj/ehz118.
11. Vaclavik J, Jelinek L, Jarkovsky J, et al. 1418 Adverse effects of spironolactone in long-term treatment of resistant arterial hypertension. European Heart Journal. 2019;40(Supplement_1): ehz748.0065. doi:10.1093/eurheartj/ehz748.0065.
12. Bogman K, Schwab D, Delporte M-L, et al. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 2017;69(1):189-96. doi:10.1161/HYPERTENSIONAHA.116.07716.
13. Freeman MW, Halvorsen Y-D, Marshall W, et al. Phase 2 Trial of Baxdrostat for TreatmentResistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi:10.1056/NEJMoa2213169.
Review
For citations:
Konradi A.O., Baranova E.I., Galyavich A.S., Zvartau N.E., Koziolova N.A., Nedogoda S.V., Falkovskaya A.Yu., Chesnikova A.I. Expert council resolution on the problem of diagnosis and treatment of resistant hypertension. Russian Journal of Cardiology. 2025;30(8):6543. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6543. EDN: JIQLMO
Views:
122
Email this article 